Transitioning biomarkers into the clinic

Area of Science:

• Gastroenterology
• Molecular Biology
• Oncology

Background:

• Colorectal cancer (CRC) remains a significant health challenge.
• Early detection and targeted therapies are crucial for improving patient outcomes.
• Understanding the molecular underpinnings of intestinal tumorigenesis is key to developing novel treatments.

Purpose of the Study:

• To investigate the molecular pathways involved in early intestinal tumorigenesis.
• To identify novel targeted agents for the management of colorectal cancer.
• To explore diagnostic, therapeutic, and immunological targets for gastrointestinal malignancies.

Main Methods:

• Focus on molecular pathway analysis in early intestinal tumorigenesis.
• Development of targeted agents based on identified pathways.
• Exploration of diagnostic and therapeutic strategies for gastrointestinal cancers.

Main Results:

• Dr. Waldman's research has led to 20 awarded patents and 30 pending patents.
• These patents cover novel diagnostic, therapeutic, and immunological targets for gastrointestinal malignancies.
• His work has resulted in over 200 publications in high-impact journals.

Conclusions:

• Dr. Waldman's research contributes significantly to the understanding of colorectal cancer.
• His work has yielded promising novel targets for the diagnosis and treatment of gastrointestinal cancers.
• The identified molecular pathways and patented targets offer potential for improved patient management and therapeutic interventions.